Research programme: recombinant methioninase - AntiCancer

Drug Profile

Research programme: recombinant methioninase - AntiCancer

Alternative Names: AC 9301; AC-9501; METase; Methioninase; ONCase; ONCase-PEG; PEG AC 9501; PEG-methioninase; PEG-rMETase; Recombinant L-methionine gamma-lyase; Recombinant methionine α, γ-lyase; rMETase

Latest Information Update: 12 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AntiCancer
  • Developer AntiCancer; Shionogi
  • Class Antineoplastics; Carbon sulfur lyases; Polyethylene glycols
  • Mechanism of Action DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer
  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Japan (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV, Infusion)
  • 24 Jul 2009 Preclinical development is ongoing in USA and Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top